Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

Dr. Joshua Hare to Chair the Board

LA JOLLA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today the formation of a Medical Advisory Board to provide clinical guidance for the Company's development program of CDP-1050 for the treatment of heart failure.

The Medical Advisory Board will play an important supportive role in the design and oversight of the planned CDP-1050 Phase 2 clinical trial and assist in addressing regulatory and patients' welfare issues. It is composed of internationally recognized leaders in the field of heart failure; all of whom have extensive experience in the design and execution of clinical trials aimed at improved care of patients with heart failure.

CDP-1050 is being developed as a new therapeutic modality in the management of heart failure. It targets the redox-nitiric oxide imbalance, which is increasingly recognized as a major factor in poor myocardial contractile efficiency, the hallmark manifestation of this disorder.

The Medical Advisory Board is chaired by Joshua M. Hare, M.D., the Louis Lemberg Professor of Medicine, Chief of the Division of Cardiology, and Director of the Interdisciplinary Stem Cell Institute at University of Miami, Miller School of Medicine. He has pioneered the use of stem cell therapy to repair damaged hearts. Dr. Hare has authored and co-authored numerous peer-reviewed publications including a report on a multi-center clinical trial with oxypurinol, a modifier of cellular redox potential, in patients with symptomatic heart failure. He served as the principal investigator of that clinical trial. Dr. Hare has also authored a New England Journal of Medicine editorial on redox-nitric oxide balance in the cardiovascular system.

Other members of the Medical Advisory Board include:

Wilson S. Colucci, M.D., is the Thomas J. Ryan Professor of
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index (MI3) ... in particular, drug/device combinations. The current system received a score of 0 (range -10 ... Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of ...
(Date:7/29/2015)... CITY , July 29, 2015 /PRNewswire/ - Aeterna ... today announced it has selected an optimized Erk ... milestone in the development of a new class ... MAPK pathway represents a prime target for therapeutic ... antitumor activities and survival benefits for B-Raf and ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences ... recruitment services. The core expertise of PRC Clinical is focused on Clinical Trial ...
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study of ... future storm surge flooding, such as occurred in Hurricane Ike in 2008. , ... protection, Costello also balanced socio-economic and environmental needs and concerns. The team ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2
... For 65 years, Mission Pharmacal Company has remained ... to provide the highest quality healthcare medications and treatments ... to be uncertain, this Texas-based company remains steadfast in ... to search for more and better prescription and consumer ...
... Fuels, Inc., (Pink Sheets: HRID ) announced ... CEO and President.  Mr. Cadena was the founder and ... Solutions, and will be instrumental in implementing the Company,s ... Mr. Cadena has over 25 years of extensive ...
... Md., Dec. 6, 2011 GenVec, Inc. (Nasdaq: ... the second milestone in its collaboration with Novartis (NYSE: ... treatments for hearing loss and balance disorders. The milestone ... development activities. "Completing this milestone reflects ...
Cached Biology Technology:Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 2Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 3Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 4Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 5Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 6Hybrid Fuels, Inc. Appoints Industry Expert as New CEO 2GenVec Achieves Second Milestone in Collaboration 2GenVec Achieves Second Milestone in Collaboration 3
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... new type of electrical generator uses bacterial spores to ... research conducted at the Wyss Institute of Biologically Inspired ... driven by changes in humidity from sun-warmed ponds and ... movement of a sheet of rubber coated on one ...
... study by Yale School of Medicine researchers provides insight into ... know about reproductive health. Published in the Jan. 27 issue ... about 50% of reproductive-age women had never discussed their reproductive ... reproductive health provider less than once a year or never. ...
... January 27, 2014 Cancer is the leading ... about 30% of all deaths, according to the Canadian ... effective drugs, it remains extremely difficult to develop anti-cancer ... at how to leverage current experimental therapies, in different ...
Cached Biology News:Getting a charge from changes in humidity 2Getting a charge from changes in humidity 3The science of baby-making still a mystery for many women 2Ottawa researchers discover new combination therapy to kill cancer 2
... Analysis Note: Protein determined by Biuret ... 25 mM Tris-HCl, pH 7.6, 1 mM ... 2 Preparation Unit Definition: One unit ... per minute at pH 9.8 at 37 ...
... Kit measures adenosine triphosphate (ATP) ... a dynamic range. Based on ... measures ATP in bacterial, plant ... concentration range of 10-11 to ...
... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...
... The RVT405DDA Refrigerated Vapor Trap is ... high boiling solvents such as DMSO ... systems. Its constant temperature refrigeration system ... optimum cryopumping conditions for DMSO, while ...
Biology Products: